Physician profile
Morgan Hatfield
NPI 1972271559
$4,397.80
in general payments reported to CMS, 2019-2025
32 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $911 · 2022: $2,685 · 2023: $409 · 2024: $172 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,785.13 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $723.93 | 2021-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $292.04 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $235.12 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $199.91 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $120.40 | 2021-2022 | |
| Janssen Biotech, INC. | $104.19 | 2022 | |
| Ardelyx, INC. | $89.74 | 2022-2023 | Ibsrela |
| Daiichi Sankyo INC. | $87.46 | 2021-2023 | Injectafer |
| Medtronic, INC. | $76.77 | 2023-2024 | Interstim |
| Braintree Laboratories, INC. | $67.39 | 2021-2022 | |
| Celgene Corporation | $62.50 | 2022 | |
| Merck Sharp & Dohme LLC | $59.59 | 2021-2022 | |
| Lilly USA, LLC | $50.14 | 2025 | Zepbound |
| Intra-Sana Laboratories | $50.00 | 2023 | Reltone 400 Mg, Reltone 200 Mg |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.91 | 2022-2025 | |
| Organon LLC | $42.89 | 2024-2025 | Nexplanon |
| Gilead Sciences, INC. | $42.19 | 2022 | |
| Shield Therapeutics INC | $39.11 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $34.58 | 2025 | |
| Boston Scientific Corporation | $22.02 | 2025 | General - Female Sui |
| Novo Nordisk INC | $19.53 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $18.85 | 2023 | |
| Lsi Solutions INC | $18.11 | 2024 | Fornisee |
| Glaxosmithkline, LLC. | $17.69 | 2025 | Nucala |
| Amgen INC. | $16.33 | 2024 | Prolia, Evenity |
| Ambu INC. | $15.56 | 2024 | |
| Alfasigma USA, INC. | $14.29 | 2022 | |
| Solventum Corporation | $13.13 | 2024 | Prevena |
| Evoke Pharma, INC. | $13.00 | 2022 | |
| Exeltis, USA INC. | $12.78 | 2023 | Slynd |
| Aspira Women'S Health INC | $9.52 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Hatfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.